![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 24, 21916-21923, June 15, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
¶
From the The vascular endothelial growth
factor (VEGF) receptor tyrosine kinase subtype kinase insert domain
receptor (KDR) contains seven extracellular Ig-like domains, of
which the three most amino-terminal contain the necessary structural
features required for VEGF binding. To clarify the functional role of
KDR Ig-like domains 4-7, we compared VEGF-induced signaling in human
embryonic kidney and porcine aortic endothelial cells expressing native
versus mutant receptor proteins in which Ig-like domains
4-7, 4-6, or 7 had been deleted. Western blotting using an
anti-receptor antibody indicated equivalent expression levels for each
of the recombinant proteins. As expected, VEGF treatment robustly
augmented native receptor autophosphorylation. In contrast, receptor
autophosphorylation, as well as downstream signaling events, were
VEGF-independent for cells expressing mutant receptors.
125I-VEGF165 bound with equal or better
affinity to mutant versus native receptor, although the
number of radioligand binding sites was significantly reduced because a
significant percentage of mutant, but not native, receptors were
localized to the cell interior. As was the case for native KDR,
125I-VEGF165 binding to the mutant receptors
was dependent upon cell surface heparan sulfate proteoglycans, and
125I-VEGF121 bound with an affinity equal to
that of 125I-VEGF165 to the native and mutant
receptors. It is concluded that KDR Ig-like domains 4-7 contain
structural features that inhibit receptor signaling by a mechanism that
is independent of neuropilin-1 and heparan sulfate proteoglycans. We
speculate that this provides a cellular mechanism for blocking unwanted signaling events in the absence of VEGF.
Cardiology Division, Department of Medicine,
and the Department of Pathology, Albert Einstein College of Medicine,
Bronx, New York 10461 and § Sibtech,
Newington, Connecticut 06111
This article has been cited by other articles:
![]() |
F. Mac Gabhann and A. S. Popel Differential binding of VEGF isoforms to VEGF receptor 2 in the presence of neuropilin-1: a computational model Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2851 - H2860. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. C. Colombo, A. W. Ashton, S. Celaj, A. Talreja, J. E. Banchs, N. B. Dubois, M. Marinaccio, S. Malla, J. Lachmann, J. A. Ware, et al. Biopsy coupled to quantitative immunofluorescence: a new method to study the human vascular endothelium J Appl Physiol, March 1, 2002; 92(3): 1331 - 1338. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hamma-Kourbali, R. Vassy, A. Starzec, V. Le Meuth-Metzinger, O. Oudar, R. Bagheri-Yarmand, G. Perret, and M. Crepin Vascular Endothelial Growth Factor 165 (VEGF165) Activities Are Inhibited by Carboxymethyl Benzylamide Dextran That Competes for Heparin Binding to VEGF165 and VEGF165{middle dot}KDR Complexes J. Biol. Chem., October 19, 2001; 276(43): 39748 - 39754. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |